Quick Detail
Place of Origin
Brand Name
Jinlan
HS-CODE
-
Package & Delivery Lead Time
Package
1g,10g,20g,
Detailed Description
Description
Acalabrutinib is a second‑generation, highly selective, covalent BTK inhibitor designed to minimize off‑target kinase activity. It binds irreversibly to BTK, blocking B‑cell receptor signaling and inhibiting proliferation and survival of malignant B cells.
Approved Indications
- Mantle cell lymphoma (MCL) in adults
- Chronic lymphocytic leukemia (CLL) / small lymphocytic lymphoma (SLL) in adults
Key Features
- High selectivity for BTK, low off‑target inhibition
- Improved safety profile compared to first‑generation BTK inhibitors
- Twice‑daily oral dosing
- Rapid and sustained BTK inhibition
Applications
API, intermediates, reference standards for R&D, generic registration and commercial manufacturing.
China [CN] 
Click enlarge Image